Olanzapine for the treatment of bipolar disorder in children and adolescents.
BACKGROUND
The second-generation antipsychotic olanzapine has been shown to be efficacious as a treatment for adults with bipolar disorder and is approved by the United States Food and Drug Administration for the treatment of acute manic or mixed episodes as well as for maintenance treatment in bipolar adults.


OBJECTIVE
This review examines the use of olanzapine for the treatment of children and adolescents with bipolar disorder and presents a discussion of the mechanism of action, pharmacokinetic and pharmacodynamic properties of olanzapine in children and adolescents. In addition, efficacy and safety data are reviewed and the risks and benefits of using olanzapine in bipolar youth are summarized.


METHODS
Articles published in English were identified using a search of the National Library of Medicine from 1990 to 2007 with manual review of references of each article as well as review of the US Clinical Trials database. Articles describing the use of olanzapine in children or adolescents were included.


CONCLUSIONS
Olanzapine appears to have a rapid onset of action for mixed and manic episodes, but is associated with metabolic side effects including hyperprolactinemia, diabetes and weight gain. Therefore, olanzapine may best be used in the acute treatment of children and adolescents experiencing a manic or mixed episode as its side-effect profile may limit its use as a maintenance agent in this population.
Strawn
Jeffrey R
JR
Department of Psychiatry, University of Cincinnati, Box 670559, Cincinnati, OH 45267-0559, USA. strawnjr@uc.edu
Delbello
Melissa P
MP
D000293:Adolescent; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001569:Benzodiazepines / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D001714:Bipolar Disorder / Q000188:drug therapy*; D002648:Child; D003920:Diabetes Mellitus / Q000139:chemically induced; D006801:Humans; D006966:Hyperprolactinemia / Q000139:chemically induced; D000077152:Olanzapine; D015430:Weight Gain / Q000187:drug effects
D014150:Antipsychotic Agents; D001569:Benzodiazepines; D000077152:Olanzapine